Journal
CURRENT OPINION IN MICROBIOLOGY
Volume 52, Issue -, Pages 100-109Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/j.mib.2019.06.002
Keywords
-
Categories
Funding
- Wellcome Trust [214229_Z_18_2]
- Biotechnology & Biological Sciences Research Council [BB/N014677/1]
- King's Health Partners Challenge Fund [R170501]
- NIH Research at Guys and St. Thomas's NHS Foundation Trust and the King's College London Biomedical Research Centre [IS-BRC-1215-20006]
- National Institutes of Health [R37-DE022550]
- Deutsche Forschungsgemeinschaft CRC/TR FungiNet Project Cl
- H2020-H2020-Marie Sklodowska-Curie Actions-European Training Networks-Marie Sklodowska-Curie grant [642095, 812969]
- BBSRC [BB/N014677/1] Funding Source: UKRI
- MRC [MC_PC_16048] Funding Source: UKRI
- Marie Curie Actions (MSCA) [642095, 812969] Funding Source: Marie Curie Actions (MSCA)
Ask authors/readers for more resources
Candidalysin is a cytolytic peptide toxin secreted by the invasive form of the human pathogenic fungus, Candida albicans. Candidalysin is critical for mucosal and systemic infections and is a key driver of host cell activation, neutrophil recruitment and Type 17 immunity. Candidalysin is regarded as the first true classical virulence factor of C. albicans but also triggers protective immune responses. This review will discuss how candidalysin was discovered, the mechanisms by which this peptide toxin contributes to C. albicans infections, and how its discovery has advanced our understanding of fungal pathogenesis and disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available